We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

1 hedge funds and large institutions have $358 invested in Acceleron Pharma in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HNB
1
Huntington National Bank
Ohio
$358 – – –

XLRN Hedge Fund Activity: Q4 2022 in Review

1 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2022, worth a combined $358.

Fund positioning in XLRN was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Acceleron Pharma (XLRN) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $358 of Acceleron Pharma stock for Q4 2022.
  • 0 funds opened new Acceleron Pharma positions in Q4 2022 and 0 closed out.

Based on aggregated 13F filings for Q4 2022.